
AS 2444697
CAS No. 1287665-60-4
AS 2444697 ( AS2444697 | AS-2444697 )
产品货号. M11172 CAS No. 1287665-60-4
一种有效的、选择性的、口服生物可利用的 IRAK-4 抑制剂,以亚纳摩尔级有效抑制人和大鼠 IRAK-4 活性。
纯度: >98% (HPLC)






规格 | 价格/人民币 | 库存 | 数量 |
5MG | ¥721 | 有现货 |
![]() ![]() |
10MG | ¥1126 | 有现货 |
![]() ![]() |
25MG | ¥2252 | 有现货 |
![]() ![]() |
50MG | ¥3686 | 有现货 |
![]() ![]() |
100MG | ¥6383 | 有现货 |
![]() ![]() |
200MG | ¥8667 | 有现货 |
![]() ![]() |
500MG | 获取报价 | 有现货 |
![]() ![]() |
1G | 获取报价 | 有现货 |
![]() ![]() |
生物学信息
-
产品名称AS 2444697
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述一种有效的、选择性的、口服生物可利用的 IRAK-4 抑制剂,以亚纳摩尔级有效抑制人和大鼠 IRAK-4 活性。
-
产品描述A potent, selective, orally bioavailable IRAK-4 inhibitor that potently inhibits human and rat IRAK-4 activity with subnanomolar order, >30-fold selectivity over IRAK-1; inhibited IL-1β- or TLR ligand lipopolysaccharide (LPS)-induced IL-6 production in human lung alveolar epithelial cells, fibroblast-like synoviocytes, and peripheral blood mononuclear cells; significantly reduces urinary protein excretion and preventd the development of glomerulosclerosis and interstitial fibrosis without affecting the blood pressure in mice model of chronic kidney disease.
-
体外实验——
-
体内实验AS2444697 is efficacious in the rat adjuvant-induced arthritis (ED50 2.7 mg/kg, BID, PO) and the rat collagen-induced arthritis (ED50 1.6 mg/kg, BID, PO) disease models. Good bioavailability was seen in rat (F% 50) and dog (F% 78) pharmacokinetic studies.AS2444697 (0.3-3 mg/kg) significantly increases the plasma levels of IL-1β, IL-6, TNF-α, MCP-1, and aminotransferases (ALT and AST) in LPS/GalN-treated mice. Single administration of AS2444697 (0.3-3 mg/kg) dose-dependently decreases plasma levels of these all parameters, and these effects were significant at doses of 1 mg/kg or higher. After oral administration of AS2444697 (3 mg/kg) to 5/6 Nx rats, plasma, and tissue (liver and kidney) concentrations of the unchanged drug peaked at 1 h and then gradually decreased, with a terminal half-life of 2.7-2.9 h. Animal Model:Male 6-week-old Wistar rats and Balb/c mice Dosage:0.3-3 mg/kg Administration:Single administration; orally Result:The plasma levels of IL-1β, IL-6, TNF-α, MCP-1, and aminotransferases (ALT and AST) were significantly increased.
-
同义词AS2444697 | AS-2444697
-
通路Immunology/Inflammation
-
靶点IRAK
-
受体IRAK
-
研究领域——
-
适应症——
化学信息
-
CAS Number1287665-60-4
-
分子量432.865
-
分子式C19H21ClN6O4
-
纯度>98% (HPLC)
-
溶解度In Vitro:?DMSO : ≥ 12.5 mg/mL (28.88 mM)
-
SMILESCC1=NC=CC(=C1)C2=NC(=CO2)C(=O)NC3=CN(N=C3C(=O)N)C4CCOCC4.Cl
-
化学全称N-[3-carbamoyl-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl]-2-(2-methylpyridin-4-yl)-1,3-oxazole-4-carboxamide hydrochloride
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Kondo M, et al. Naunyn Schmiedebergs Arch Pharmacol. 2014 Oct;387(10):909-19.
2. Imanishi J, et al. Arthritis Rheum 63:S390.
产品手册




关联产品
-
IRAK-4 protein kinas...
IRAK-4 蛋白激酶抑制剂 2 是一种有效的白细胞介素 1 受体相关激酶 4 (IRAK-4) 抑制剂 (IC50 = 4 μM)。
-
Zabedosertib
Zabedosertib (BAY 1834845) 是一种选择性的,口服有效的 IRAK4 抑制剂,具有免疫调节潜能,IC50 值为 3.55 nM。IRAK4 是一种参与 toll 样受体的先天免疫反应信号的蛋白激酶。Zabedosertib 对 IL-β,LPS (HY-D1056) 和 Imiquimod (HY-B1080) 诱导的炎症具有抗炎作用。
-
HG-12-6
HG-12-6 是一种小分子抑制剂,优先与未磷酸化的 IRAK4 结合,IC50 为 165.1 nM。